In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Nitrosamines in medicinal products: report results of risk assessments for impurities

Nitrosamines in medicinal products: report results of risk assessments for impurities

by In2Pharma | Nov 6, 2019 | News

Belgium As a precaution, the European Medicines Agency (EMA) and European medicines authorities asked marketing authorisation holders in October 2019 to perform a risk assessment on the presence of nitrosamines. The Federal Agency for Medicines and Health Products...

Recent Posts

  • Junior Consultant vacancy
  • Register your Industry Single Point of Contact (i-SPOC) on supply and availability
  • Update Commission Regulation regarding monacolins from red yeast rice
  • The FAMHP launches the Medicinal Product Management database
  • Request to marketing authorisation holders to send the approved version of the risk management plan

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België